Business
Cell MedX Corp. Files Premarket Notification (510K) with the US Food and Drug Administration and Receives Canadian Trademark
Cell MedX Corp. Files Premarket Notification (510K) with the US Food and Drug Administration and Receives Canadian Trademark.
About this update from Stimcell Energetics Inc.
[{"type":"text","content":"Carson City, Nevada--(Newsfile Corp. - September 17, 2021) - Cell MedX Corp. (OTCQB: CMXC) (\"Cell MedX\" or the \"Company\"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has submitted a premarket notification (510K) to the U.S. Food and Drug Administration (FDA) for the eBalance® Home System and eBalance® Pro System.The eBalance® Pro System and eBalance® Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities (legs) due to strain from exercise or normal household- or work-related activities, as well as for general relaxation. The eBalance® Pro System is intended for use by professionals in the clinical setting and the eBalance® Home System is intended for home use by laypersons. Frank McEnulty, the Company's CEO and Director, stated, \"Today marks an important milestone in our commitment to our future customers and patients within the United States. The 510(K) submission is the first step in the review process with the FDA, and we look forward to working through the FDA review process to obtain clearance and gain entry into the US market.\"In addition, the Company wishes to announce that on August 16th the Canadian Intellectual Property Office approved the Company's EBALANCE trademark application number 1867918 and issued certificate of registration number 1,104,935 registering the trademark EBALANCE in the name of the Company. The Company's applications to register EBALANCE as a trademark in the United States, which the Company filed with the United States Patent and Trademark Office on December 11, 2017, continue to be under review. About Cell MedX Corp. (OTCQB: CMXC) Cell MedX Corp. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson's disease, high blood pressure, neuropathy and kidney function. The Company's main focus ...